NuProbe

NuProbe is a privately held, US-based company founded in 2016 with a mission to improve the analytical sensitivity of DNA biomarker detection for cancer research and diagnostics. Its core technology platform includes Blocker Displacement Amplification (BDA) for rare allele enrichment on PCR/digital PCR and Quantitative Amplicon Sequencing (QASeq) for highly multiplexed, UMI-based NGS assays. The company has secured a significant $50M funding round, entered a key licensing agreement with Bio-Rad, and operates with a dual business model of developing research-use assays and providing custom assay development services to biopharma. NuProbe is positioned to address the growing need for sensitive liquid biopsy and tissue-based testing in oncology.

Proprietary Blocker Displacement Amplification (BDA) for PCR/dPCR and Quantitative Amplicon Sequencing (QASeq) for NGS, enabling ultrasensitive (down to 0.01% VAF) detection of low-frequency mutations, CNVs, and fusions.

NuProbe competes in the ultrasensitive detection segment against companies like ArcherDX/Invitae (AnchorIRMA), Sysmex Inostics (Safe-SeqS), and various NGS panel providers. Its differentiation lies in the dual-platform approach (BDA for PCR, QASeq for NGS) and very high claimed sensitivity. The exclusive Bio-Rad partnership provides a unique position in the dPCR segment.